Posted by Michael Wonder on 03 Jul 2023
Organon & Samsung Bioepis announce US launch of Humira biosimilar Hadlima (adalimumab-bwwd) in multiple presentations consistent with originator
1 July 2023 - Individualised patient support program “Hadlima For You” available including co-pay support.
Organon & Samsung Bioepis today announced that Hadlima (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab), is now available to patients in the US. Consistent with Humira, Hadlima is available in both citrate-free high concentration (100 mg/mL) and citrate containing low concentration (50 mg/mL) to provide patients with seamless continuity of care.
